Arcturus Therapeutics (United States)

Recent papers from Arcturus Therapeutics (United States)

1. Extended dosing intervals enhance the durability of a self-amplifying mRNA vaccine against pandemic H5N1 influenza: a randomized, observer-blind, dose-finding Phase I studyNature Communications · 2026
2. Sustained Humoral Activation through self-amplifying mRNA Vaccination Enhances Longitudinal Antibody Function in a Phase III Trial 2305471The Journal of Immunology · 2026
3. Self-amplifying COVID-19 mRNA vaccination induces longitudinally enhanced antibody function in a Phase 3 trialnpj Vaccines · 2026
4. Targeted Epigenetic Modulation Outperforms Nuclease- and Deaminase-Based Editing for Durable Pcsk9 Silencing in a Clinically Relevant Delivery System2026
5. mRNA COVID-19 Vaccines: Science vs. MisinformationRNA · 2026
6. Peptide Substitutes of PEG: Biological Outcomes on Prospective Lipid Nanoparticle Shielding Materials.2026
7. Immunogenicity and safety of self-amplifying mRNA COVID-19 vaccine (ARCT-2303), with or without co-administration of seasonal inactivated influenza vaccine in adults: a phase 3, randomised, controlled, observer-blind, multicentre studyEClinicalMedicine · 2025
8. The Veil of Gender: De-Sensationalizing the Lethality of Female Suicide TerrorismJournal of Global Security Studies · 2025
9. Design and Evaluation of Biodegradable Self‐Immolative Lipids for RNA DeliveryAdvanced Healthcare Materials · 2025
10. Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical studyNature Communications · 2025
11. Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: a pooled phase 1/2/3 randomized clinical studyExpert Review of Vaccines · 2025
12. Blood and tissue HIV-1 reservoirs display plasticity and lack of compartmentalization in virally suppressed peopleNature Communications · 2025
13. Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GP(1,2) in a position elevated from the virion membraneNature Communications · 2025
14. A randomized trial comparing safety, immunogenicity and efficacy of self-amplifying mRNA and adenovirus-vector COVID-19 vaccinesnpj Vaccines · 2024
15. Lipid nanoparticle delivery of TALEN mRNA targeting LPA causes gene disruption and plasma lipoprotein(a) reduction in transgenic miceMolecular Therapy · 2024
16. A lipid nanoparticle-based oligodendrocyte-specific mRNA therapyMolecular Therapy — Nucleic Acids · 2024
17. Preclinical evaluation of a fully human, quadrivalent-hantavirus polyclonal antibody derived from a non-human sourcemBio · 2024
18. Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targetsAntimicrobial Agents and Chemotherapy · 2024
19. Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trialsNature Communications · 2024
20. Potent latency reversal by Tat RNA-containing nanoparticle enables multi-omic analysis of the HIV-1 reservoirNature Communications · 2023